The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CAP accreditation

1 Sep 2022 07:20

RNS Number : 9032X
Open Orphan PLC
01 September 2022
 

Open Orphan plc

("Open Orphan" or the "Company")

 

Clinical laboratories achieves CAP accreditation

 

Confirms hVIVO laboratories high standard of excellence

 

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that its clinical laboratories in Queen Mary's Bioenterprise Centre and Plumbers Row (hLab) have been awarded accreditation by the College of American Pathologists ("CAP"). The Company sought the accreditation as part of its ongoing commitment to maintaining best in class quality systems.

 

The CAP is the world's largest organisation of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programmes. The accreditation "supports laboratories performing testing on specimens from human, using methodologies and clinical application within the expertise of the program". This further expands on the Company's Good Clinical Practice for Laboratories (GCLP) accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA) and provides additional quality assurances of its laboratory services for its clients, especially within the United States, thus ensuring the accuracy of test results and conforming to the requirements from the US Food and Drug Administration (FDA).

 

hLab is a highly specialised virology and immunology laboratory, offering a suite of services to support both pre-clinical and clinical respiratory drug and vaccine discovery and development. This includes assay development, transfer and optimisation across immunology, molecular and cell-based assays, including extensive options in sample matrix and stability testing and analysis. hLab is well equipped with Biosafety Level 2 and 3 facilities to provide high quality data outputs to enable clients to achieve early proof of concept, or to make a breakthrough discovery in the pathology and possible treatment of diseases with unmet medical needs. hLAB now provides services beyond supporting the Company's in-house human challenge trials, offering lab services as a standalone service to support vaccine and drug development from pre-clinical studies through Phases I - III clinical trials.

 

Brandon Londt, Development Operations Director, hLab Development at hVIVO, said: "We are proud to have received the CAP accreditation, which is recognition of the quality of our laboratory and further demonstrates our commitment to maintaining the highest standards of excellence and ensuring that our work practices meet the rigorous CAP assessment standards. This accreditation will provide current and future clients a further degree of confidence in the quality of work performed in our laboratory and assurances of the results we produce."

 

 

For further information please contact:

 

Open Orphan plc

+44 (0) 20 7756 1300

Yamin Khan, Chief Executive Officer

Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Phillip Marriage /Louis Ashe-Jepson

+44 (0)20 7933 8780 or openorphan@walbrookpr.com

+44 (0) 7796 794 663 / +44 (0) 7867 984 082 /+44 (0) 7747 515 393

 

Notes to Editors

 

Open Orphan plc

 

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing contract research company that is a world leader in testing infectious and respiratory disease products using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organisations.

 

The Company has a leading portfolio of human challenge study models for infectious and respiratory diseases, including the recently established COVID-19 model, and is developing a number of new models, such as Malaria, to address the dramatic growth of the global infectious disease market. The Paris and Breda offices have over 25 years of experience providing drug development services such as biometry, data management, statistics CMC, PK and medical writing to third party clients as well as supporting the London-based challenge studies.

 

Open Orphan runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its newly opened clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. The newly opened facilities have expanded the scope of the business to enable the offering of Phase I and Phase II vaccine field trials, PK studies, bridging studies, and patient trials as part of large international multi-centre studies.

 

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion® platform, this unique dataset includes clinical, immunological, virological, and digital (wearable) biomarkers.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABKDBDABKKACK
Date   Source Headline
12th Dec 20194:41 pmRNSForm 8.3 - Open Orphan PLC
11th Dec 20194:03 pmRNSForm 8.3 - Open Orphan
11th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 201911:13 amGNWForm 8.3 - Open Orphan
11th Dec 20197:00 amRNSForm 8 (OPD)
10th Dec 20194:43 pmRNSForm 8 (DD) Open Orphan plc
10th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
10th Dec 20199:59 amPRNForm 8.3 - Open Orphan
10th Dec 20197:00 amRNSRule 2.9 Announcement
9th Dec 20191:27 pmRNSTotal Voting Rights
9th Dec 201912:21 pmPRNForm 8.3 - Open Orphan Plc
9th Dec 20197:00 amRNSRecommended All-Equity Offer
25th Nov 20197:00 amRNSEarly adopters signed for Genomic Health DataBANK
18th Nov 20197:00 amRNSContract signed with Carna Bioscience
15th Nov 20197:00 amRNSJefferies 2019 London Healthcare Conference
11th Nov 20197:00 amRNSPreferred Partner Agreement
24th Oct 20197:00 amRNSValue the Markets Webinar
21st Oct 20197:00 amRNSInvestor Event Attendance and Presentation
15th Oct 20197:00 amRNSAgreement signed with Empiric Logic
8th Oct 20197:00 amRNSInvestor Event Attendance and Presentation
2nd Oct 20193:58 pmRNSResult of AGM
1st Oct 201911:08 amRNSHolding(s) in Company
27th Sep 20198:00 amRNSEuronext Growth Dublin Notice
25th Sep 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
23rd Sep 20193:39 pmRNSExercise of Warrants and Issue of Shares
16th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
12th Sep 20197:00 amRNSNotice of AGM
10th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
9th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
3rd Sep 20197:00 amRNSInvestor Event Attendance and Presentation
2nd Sep 20197:00 amRNSUpcoming Investor Events
1st Aug 20197:00 amRNSDirectorate Changes
30th Jul 20198:00 amRNSEuronext Growth Dublin Notice
25th Jul 20197:00 amRNSExercise of Warrants and Issue of Shares
12th Jul 20197:00 amRNSChange to interests of a significant shareholder
12th Jul 20197:00 amRNSIntegumen Shares
9th Jul 20195:26 pmRNSHolding(s) in Company
28th Jun 20198:00 amRNSEuronext Growth Dublin Notice
28th Jun 20197:59 amRNSEuronext Growth Dublin Cancellation Notice
28th Jun 20197:00 amRNSFirst Day of Dealings and Re-admission
25th Jun 20191:24 pmRNSDirectorate Update
14th Jun 201912:13 pmRNSEuronext Growth - Schedule One
14th Jun 201911:00 amRNSSchedule One - Ven Life Sciences Holdings plc
11th Jun 20197:30 amRNSEuronext Growth Dublin Market Restoration Notice
11th Jun 20197:30 amRNSRestoration - Venn Life Sciences Holding Plc
11th Jun 20197:01 amRNSPlacing of Shares
11th Jun 20197:00 amRNSAudited Final Results
10th May 20197:30 amRNSEuronext Growth Dublin Suspension Notice
10th May 20197:30 amRNSSuspension - Venn Life Sciences Holdings Plc
10th May 20197:01 amRNSConditional Acquisition of Open Orphan DAC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.